E23.1

Drug-induced hypopituitarism

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC ESRD V24

HCC23

Other Significant Endocrine and Metabolic Disorders

RxHCC V08

RXHCC43

Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

This code · E23.1

Use additional

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Inherited from E23Hypofunction and other disorders of the pituitary gland

Includes

the listed conditions whether the disorder is in the pituitary or the hypothalamus

Excludes 1

postprocedural hypopituitarism (E89.3) short stature due to endocrine disorder (E34.3-)

Inherited from E20-E35Disorders of other endocrine glands

Excludes 1

galactorrhea (N64.3) gynecomastia (N62)

Inherited from chapter 4Endocrine, nutritional and metabolic diseases

Excludes 1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Official Guidelines for E23.1

FY 2026 ›

I.C.4Chapter-specific guidanceChapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00-E89)

Subsections

Find E23.1 in the alphabetic index

2 index paths lead to this code